Line 39: | Line 39: | ||
==References == |
==References == |
||
1. Batshaw ML, et al. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138 (suppl 1): S46-S55. (PubMed id:11148549) Correction. ibid. 2002; 140: 490. |
1. Batshaw ML, et al. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138 (suppl 1): S46-S55. (PubMed id:11148549) Correction. ibid. 2002; 140: 490. |
||
2. Kang HL, Benzer S, Min KT.; Life extension in Drosophila by feeding a drug.; |
|||
Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):838-43. Epub 2002 Jan 15.; PMID: 11792861 |
Revision as of 11:57, 14 September 2006
File:Phbutyrate.jpg | |
Clinical data | |
---|---|
License data |
|
Pregnancy category |
|
ATC code | |
Pharmacokinetic data | |
Metabolism | to phenylacetate |
Excretion | 80% as phenylacetylglutamine |
Identifiers | |
| |
CAS Number | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.130.318 |
Chemical and physical data | |
Formula | C10H11NaO2 |
Molar mass | 186.2 g·mol−1 |
Sodium Phenylbutyrate is an orphan drug, marketed by Ucyclyd Pharma (Hunt Valley, USA) under the trade name Buphenyl® and by Orphan Europe (France) as Ammonaps®. Phenylbutyrate is a prodrug. In the human body it is metabolized by beta-oxidation to phenylacetate. Phenylacetate conjugate with glutamine to phenylacetylglutamine, that is eliminated with the urine.
Sodium phenylbutyrate is also under investigation for the treatment of some sickle-cell disorders (Blood Products Plasma Expanders and Haemostatics) and for use as a potential differentiation-inducing agent in malignant glioma and acute myeloid leukaemia.
References
1. Batshaw ML, et al. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138 (suppl 1): S46-S55. (PubMed id:11148549) Correction. ibid. 2002; 140: 490.
2. Kang HL, Benzer S, Min KT.; Life extension in Drosophila by feeding a drug.; Proc Natl Acad Sci U S A. 2002 Jan 22; 99(2):838-43. Epub 2002 Jan 15.; PMID: 11792861